Default company panoramic image
Logo

Bionure

Early-stage drug development company developing a game-changing, neuroprotective and remyelinating drug for the treatment of MS and orphan diseases ON and NMO.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Barcelona, Spain
  • Currency USD
  • Founded 2009
  • Employees 7
  • Website bionure.com

Company Summary

Bionure is an early-stage drug development company founded in 2009 based in Barcelona and San Jose, California. Bionure develops neuroprotective therapies for neurodegenerative diseases with special focus in Multiple Sclerosis (MS) and two rare, orphan diseases: Optic Neuritis (ON) and Neuromyelitis Optica (NMO). Bionure has been granted by European Commission with an Orphan Drug Designation for BN201 for the treatment of Optic Neuritis in EU.

Team

  • Default avatar
    Mr. Albert G. Zamora
    CEO

    Co-founder, Chairman and CEO of Bionure. MBA.

    More than 15 years of professional experience in Healthcare. Senior positions in Strategic Marketing and Business Development. Experience in the Management of academic research: Director of Innovation at the Hospital Clinic de Barcelona, promoting tech transfer and Spin-Offs. Entrepreneur involved in several tech projects. Uses to teach entrepreneur skills in several business schools (EADA, IESE)

  • Default avatar
    Dr Pablo Villoslada
    CSO

    Co-founder and CSO of Bionure. MD and PhD in Neuroimmunology.

    Strong expertise as a researcher (i.e. UCSF). Director of Neuroimmunology at Hospital Clinic de Barcelona, IDIBAPS. Published >80 scientific articles about the pathogenesis and new therapies for MS. Inventor of 9 patents about the diagnosis and treatment of MS and other brain and retina diseases. Member of several Advisory Boards (Roche, Novartis, Advancell, Neurotec, Digna).

  • Default avatar
    Dr Joaquim Trias
    Strategic & Scientific advisor (Advisory Board)

    Joaquim Trias Puig-Sureda is one of the top names in the American biotech sector with more than 20 years experience in biotech development at Silicon Valley. He has helped found companies like Microcide Pharmaceuticals, Vicuron (acquired by Pfizer), Peninsula (bought by Johnson&Johnson), Anthera and Tetraphase.

  • Default avatar
    Prof Larry Steinman
    Scientific Advisor (Advisory Board)

    MD Harvard University, NIH Fellow at Harvard Medical School, and currently Professor, Departments of Neurology and Neurological Sciences, Stanford University. Co-Inventor of leading MS drug Natalizumab and several new therapies for autoimmune diseases (eg. DNA vaccination)

  • Default avatar
    Dr Craig Smith
    Scientific Advisor (Advisory Board)

    MD University of Washington, Professor of Medicine, Neurology, Ophthalmology and Neurosurgery at the University of Washington up until 2004. Currently CMO in an innovation biotech company. Ex-Clinical science Unit Head, Ophthalmology and eHealth Global Strategic Lead, Novartis.

  • Default avatar
    Prof Stephen L. Hauser
    Scientific Advisor (Advisory Board)

    MD Harvard Medical School and currently Professor and Chair, Department of Neurology, UCSF. Dr. Hauser has been appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues.